A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

NCT02332668 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

370

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma
Lymphoma
Solid Tumor
Classical Hodgkin Lymphoma
Microsatellite-instability-high Solid Tumor

Interventions

BIOLOGICAL: Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC